Compare Amylx Pharmaceuticals Inc (AMLX) vs Vanguard Ultra Short Bond ETF (VUSB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amylx Pharmaceuticals Inc vs Vanguard Ultra Short Bond ETF — how do they compare? Amylx Pharmaceuticals Inc trades at $23.96 (market cap $2.64B), while Vanguard Ultra Short Bond ETF trades at $49.67. The key difference: Amylx Pharmaceuticals Inc is trading nearer its 52-week high, Vanguard Ultra Short Bond ETF nearer its low. Which is the better fit depends on your goals.
| AMLX | VUSB | |
|---|---|---|
Market Cap | $2.64B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $24.19 | $50.03 |
52-Week Low | $7.82 | $49.60 |
Enterprise Value | $2.39B | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amylx Pharmaceuticals Inc
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →About Vanguard Ultra Short Bond ETF
VUSB is an actively managed ETF from Vanguard that invests in a diversified portfolio of high-quality, investment-grade fixed income securities with maturities typically under two years. It is designed to offer higher yield potential than traditional money market funds while maintaining limited price volatility, making it a strategic tool for managing short-term reserves with a 6-to-18-month horizon.
Read more on VUSB →
